ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 574,78
-0,76%
Dow Jones
40 211,72
0,53%
DAX
18 505,40
-0,51%
Brent Oil
83,125
-1,44%
Bitcoin
63 684,69
-1,80%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
08/12/200915h15Business WireAllos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200919h22Dow Jones News2nd UPDATE: Celgene To Buy Gloucester Pharma for At Least $340 MillionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200916h00Business WireAllos Therapeutics’ FOLOTYN™ Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Tre...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200914h41Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/200916h00Business WireAllos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN™ at 51st ASH Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/200914h00Business WireAllos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN™ (pralatrexate injection)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/12/200914h00Business WireAllos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematolo...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/11/200914h00Business WireAllos Therapeutics Announces Issuance of U.S. Patent for FOLOTYNNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/11/200912h38MarketwiredRidgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn EnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200914h00Business WireAllos Therapeutics Announces New Data on FOLOTYN™ to be Presented at the American Society of Hematology MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200912h54MarketwiredAnalystChoice.com Provides Analytical Coverage on ELNK, NWSA, NTAP, ALTH, HANS and BPOPNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200915h51Business WireAllos Therapeutics to Present at Upcoming Conferences in NovemberNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200922h11Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200922h01Business WireAllos Therapeutics Reports Third Quarter 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/11/200911h12MarketwiredGlobal Market Perspective Review on ALTH, CINF, ALKS, DBRN, APOL and INFY from TheFortuneFinancial.comNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/10/200913h00Business WireAllos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/10/200912h57MarketwiredBenchmarkJournal.com Provides Sector & Company Analysis on OMC, PSE, PWR, ALTH, NWSA and ELNKNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/10/200922h05Business WireAllos Therapeutics Announces Closing of Public OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/10/200912h40MarketwiredELNK, HERO, ABAT, NTAP, DBRN and ALTH Receives Analytical Coverage from WallStSense.comNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/10/200923h08Edgar (US Regulatory)Prospectus filed pursuant to Rule 424(b)(5) (424B5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/10/200912h19Edgar (US Regulatory)Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/10/200912h14Business WireAllos Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/10/200922h01Business WireAllos Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/10/200913h00Business WireAllos Therapeutics Announces U.S. Availability of FOLOTYN™ (pralatrexate injection) for Relapsed or Refractory Peripheral T...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/10/200923h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/10/200912h36MarketwiredRothmanResearch.com Stock Review for SCG, CA, NE, MKC, COL and ALTHNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/09/200913h00Business WireAllos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/09/200922h15Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/200900h09Business WireAllos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN™ (pralatrexate) for the Trea...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/09/200912h00Edgar (US Regulatory)Notice of Effectiveness (EFFECT)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
CAP
Capgemini
EU
PX1
CAC 40
USI
USTECH100
US Tech 100
EU
DG
Vinci
EU
RI
Pernod Ricard
EU
CS
Axa
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
NYSE
MRK
Merck
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
EU
LR
Legrand
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés